Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Sponsor

City of Hope Medical Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT06052826

Collaborator

National Cancer Institute (NCI) (NIH)

164

Enrollment

Location

Arms

39.4

Anticipated Duration (Months)

4.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). A large number of patients diagnosed with cancer are over the age of 60, yet most cancer treatments are developed for younger patients. Therefore, older patients may be less likely to be offered stronger treatments, such as CAR-T therapy, due to possible side effects. Geriatric assessment is a multi-dimensional health assessment tool combining patient reported and objective measures covering physical function, mental processes (cognitive), and nutrition. Pre-treatment assessments may identify weaknesses in older adults and may guide interventions for physical therapy, cognitive changes and nutrition to decrease CAR-T therapy side effects and improve care in older adults with NHL or MM.

Condition or Disease	Intervention/Treatment	Phase
B-Cell Non-Hodgkin Lymphoma Multiple Myeloma	Other: Best Practice Other: Cognitive Intervention Other: Comprehensive Geriatric Assessment Other: Nutritional Intervention Procedure: Physical Therapy Other: Questionnaire Administration	Phase 2

Detailed Description

PRIMARY OBJECTIVE:

Evaluate the effects of a GA-informed multi-disciplinary intervention in attenuating physical function decline among older patients receiving CAR-T therapy at day +30 post-CAR-T infusion.

SECONDARY OBJECTIVES:

Determine success in coordinating trimodality optimization before lymphodepletion.
Compare rates of geriatric syndromes of frailty, cognitive impairment and malnourishment in SOC and GA-intervention cohorts at 30 days post-CAR-T infusion.
Evaluate rates and duration of CAR-T related neurotoxicity in SOC and GA-intervention groups.

EXPLORATORY OBJECTIVES:

Quantify trimodality optimization intensity throughout treatment course. II. Compare longitudinal trajectory of Short Physical Performance Battery (SPPB), frailty, cognitive impairment and malnourishment between the two arms, at day +100 post-CAR-T infusion.
Evaluate quality of life trajectories using the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at baseline and days +30 and +100 in both cohorts.
Incidence of intensive care unit (ICU) admissions by day 100. V. Overall survival, response rate and progression-free survival through one year.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive physical therapy (PT) and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.

ARM II: Patients undergo GA and receive standard of care throughout study.

After completion of study treatment, patients are followed up at day 100 and then up to 1 year.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

164 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Supportive Care

Official Title:

Geriatric (G) Assessment Guided Optimization (O) to Accelerate Functional Recovery After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Patients 60 Years and Older With B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma (GOCART)

Actual Study Start Date :

Jun 23, 2023

Anticipated Primary Completion Date :

Oct 5, 2026

Anticipated Study Completion Date :

Oct 5, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm I (PT, cognitive education, nutrition education) Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.	Other: Cognitive Intervention Receive delirium prevention education Other: Comprehensive Geriatric Assessment Undergo geriatric assessment Other: Nutritional Intervention Undergo nutritional optimization Procedure: Physical Therapy Undergo physical function optimization Other Names: Physiatric Procedure Physical Medicine Procedure Physical Therapeutics Physical Therapy Procedure Physiotherapy Physiotherapy Procedure PT Other: Questionnaire Administration Ancillary studies
Active Comparator: Arm II (standard of care) Patients undergo GA and receive standard of care throughout study.	Other: Best Practice Undergo standard of care Other Names: standard of care standard therapy Other: Questionnaire Administration Ancillary studies

Arm

Intervention/Treatment

Experimental: Arm I (PT, cognitive education, nutrition education)

Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.

Other: Cognitive Intervention

Receive delirium prevention education

Other: Comprehensive Geriatric Assessment

Undergo geriatric assessment

Other: Nutritional Intervention

Undergo nutritional optimization

Procedure: Physical Therapy

Undergo physical function optimization

Other Names:

Physiatric Procedure

Physical Medicine Procedure

Physical Therapeutics

Physical Therapy Procedure

Physiotherapy

Physiotherapy Procedure

Other: Questionnaire Administration

Ancillary studies

Active Comparator: Arm II (standard of care)

Patients undergo GA and receive standard of care throughout study.

Other: Best Practice

Undergo standard of care

Other Names:

standard of care

standard therapy

Other: Questionnaire Administration

Ancillary studies

Outcome Measures

Primary Outcome Measures

Changes in Short Physical Performance Battery (SPPB) [From baseline to day 30 after chimeric antigen receptor T-cell (CAR-T) infusion]
T-test will be used to compare SPPB changes score between two arms at 30 days after CAR-T infusion.

Secondary Outcome Measures

Successful in coordinating initial optimization [From enrollment to start of lymphodepletion]
A physical or virtual visit will be tabulated separately for functional optimization, delirium prevention and nutrition. Adherence will be deemed to have been met if >=70% or more comlete tri-modality optimization before lymphodepletion in the modified intent to treat population.
Frailty progression [At 30 days post CAR-T infusion]
Frailty progression will be defined as a score of 3 or more at T2 if T1 not frail (<3); if frail at T1 (score 3-5), any worsening of the score; a score of 5 at day 30 if baseline score already at the maximum frailty of 5.
Cognitive impairment [At 30 days post CAR-T infusion]
Assessed using the Montreal Cognitive Assessment (MoCA). Cognitive impairment defined as MoCA score of < 23 or unable to complete the MoCA due to cognitive impairment. The proportion of patients with cognitive impairment at day 30, irrespective of baseline cognition, will be compared between the two arms using Chi-square test.
Weight loss [Up to 30 days post CAR-T infusion]
Malnourishment will be measured using weight loss and dichotomized as > 5% weight loss from baseline to day +30. The proportion of patients with over 5% weight loss from T1 to T2 will be compared between the two arms using Chi-square test.
CAR-T associated neurotoxicity [Up to day 100]
Assessed using American Society for Transplantation and Cellular Therapy consensus grading for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). The time to neurotoxicity (days), the maximum grade (1-4) and the duration of neurotoxicity (days) will be recorded. The cumulative incidence of ICANS (percentages) will be compared between arms as well as the maximum grade (1-4), and duration of neurotoxicity (days).

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Ability to provide informed consent
Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care
Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures
Age: >= 60 years at the time of enrollment
Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma
Willing and able to complete study requirements
Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits

Exclusion Criteria:

Prior CAR-T therapy
Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)